Neuroendovascular Coil Market Size & Trends
The size of the global neuroendovascular coil market was approximated at USD 1.04 billion in 2024 and is expected to increase at a CAGR of 6.5% from 2025 to 2030. The market growth is due to the rising prevalence of cerebral aneurysms and stroke driven by aging populations and lifestyle-related factors such as hypertension, smoking, and diabetes.
Key Highlights
- North America neuroendovascular coil market dominated the global market with a revenue share of 36.71% in 2024
- The U.S. held the largest share in North America neuroendovascular coil market in 2024.
- By type segment, bare platinum coils dominate the market due to their long-established clinical efficacy and widespread adoption.
- In terms of application segment, the cerebral aneurysm application segment dominates the market.
- By end use segment, the hospital segment dominates the market due to its advanced infrastructure, specialized personnel, and comprehensive emergency care capabilities.
Technological innovation has greatly improved procedural efficiency and safety, such as the creation of the next-generation detachable, hydrogel-coated, and 3D complex coils. Based on the data of NIH 2025, annually, an estimated 795,000 individuals in the U.S. have a stroke, with about 610,000 of these being first-time strokes. Almost one in four stroke survivors will have a repeat stroke. Of all stroke cases, around 87% are ischemic strokes and the other 13% hemorrhagic strokes.
The aged population heavily influences the neuroendovascular coil market since the incidence of neurological conditions and disease, e.g., aneurysm, is rising with age. With the growing elderly population, there is an increased demand for minimally invasive procedures, like neuroendovascular coil embolization, as they are safer and have faster recovery compared to conventional surgery. Furthermore, the greater risk of complications among elderly patients, including aneurysms rupturing or strokes, also increases the demand for neuroendovascular coils. Healthcare systems globally are responding to the demands of aging populations, adding treatment facilities, and constructing desirable reimbursement policies, thereby expanding the market. In addition, the emphasis on enhancing quality of life in older people adds to the increased need for advanced, minimally invasive solutions like neuroendovascular coils and thus fuels the growth in the market.
The following graph shows estimated figures regarding the percentage of the population 65 and above in different OECD countries by 2050, indicating the worldwide pattern of population aging. Other nations like South Korea (39.8%), Japan (37.7%), and Italy (33.7%) will have the largest percentages of elderly populations, reflecting fast-paced demographic changes due to heightened life expectancy and falling birth rates. This further implies an increased need for age-specific medical treatments and devices, including neuroendovascular coils, as instances of diseases like stroke are likely to increase with the aging population.
Hypertension is also one of the major risk factors for a wide range of vascular diseases, such as cerebral aneurysms, strokes, and other cerebrovascular anomalies. Its increasing incidence worldwide is one of the key drivers for the growth of the neuroendovascular coil market. Neuroendovascular coils find universal applications in minimally invasive treatments of brain aneurysms and vascular malformations, which are precipitated or worsened by uncontrollable hypertension. Hypertension is the main etiology of hemorrhagic strokes. It leads to the narrowing and hardening of arteries, which makes them prone to occlusion or rupture. Neuroendovascular intervention, with the deployment of coils, is a first-line treatment for hemorrhagic strokes due to ruptured aneurysms. The growing global burden of hypertension, particularly in low- and middle-income nations where blood pressure management is inadequate, is likely to increase stroke incidence, thus driving the demand for neuroendovascular interventions. According to the British Heart Foundation BHF, 2025, it is estimated that around 30% of UK adults, approximately 16 million people, are living with high blood pressure, and up to half of them are not receiving effective treatment. While about 11 million individuals have been diagnosed by their general practitioner, this suggests that up to 5 million adults may remain undiagnosed. Together, as many as 8 million individuals in the UK may be unaware that they have uncontrolled or undiagnosed high blood pressure.
Aneurysms of the brain, which are caused when blood vessels become weak and develop a bulge, are also a worry for the elderly population. The risk of aneurysms increases with age, particularly after age 50. As the number of elderly individuals rises globally, the occurrence of aneurysms has become more prevalent, fueling demand for treatment options. Neuroendovascular coils are among the most sought-after treatments for these aneurysms since they use less invasive methods compared to conventional surgery, thus being more comfortable for old patients who have other underlying medical conditions or are not able to withstand more invasive surgeries.
From the Brain Aneurysm Foundation 2024,
Around 6.8 million individuals in the U.S. possess an unruptured brain aneurysm 1 in 50 individuals.
The yearly rupture rate is approximately 8-10 per 100,000 individuals.
Approximately 30,000 individuals in the United States experience a brain aneurysm rupture yearly one rupture each 18 minutes.
Almost 500,000 fatalities globally are attributed to brain aneurysms every year.
Brain aneurysm cases are half under the age of 50.
Market Concentration & Characteristics
The stage of market growth is elevated, and growth rate is increasing. Newer neuroendovascular coils are constructed from shape-memory and biocompatible alloys, including platinum, nitinol, or composites that are more flexible, more visible under fluoroscopy, and more thrombogenic. Hydrogel-coated coils are also being designed that expand when they come into contact with blood, completely filling aneurysms and decreasing rates of recurrence. Conventional helical coils have become intricate three-dimensional (3D) shapes, including framing, filling, and finishing coils, that enhance packing density and are more conformable to the aneurysm sac.
Mergers and acquisitions activity in the neuroendovascular coil market has been moderate, indicative of the market's growth opportunity, technical sophistication, and greater strategic interest among large medical device manufacturers. Multiple reasons fuel the trend, such as portfolio expansion, technological integration, access to global markets, and consolidation in a competitive market. Top neurovascular players have been acquiring smaller, innovative companies aggressively to enhance their neuroendovascular product lines. For example, Stryker finalized its acquisition of Cerus Endovascular Ltd., a privately owned medical device company focused on neurointerventional devices for intracranial aneurysm treatment, in May 2023. Cerus Endovascular's CE-marked offerings, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, should increase Stryker's portfolio of aneurysm treatment options.
These products meet the increasing demand for one-and-done intrasaccular aneurysm therapy.
Regulatory requirements play a major role in the neuroendovascular coil market, touching product development, approval, commercialization, as well as post-market surveillance. Tight regulatory standards, especially in the United States and Europe, influence the cost and duration of bringing new products to market. In the United States, the FDA's 510(k) and Premarket Approval (PMA) approval processes involve rigorous clinical trials and considerable proof of safety and effectiveness. Likewise, the European Union's Medical Device Regulation (EU MDR) has established stricter regulations than its predecessor, requiring comprehensive clinical testing, risk analysis, and documentation. Though critical to patient safety and device reliability, these regulations can become formidable barriers to entry, particularly for small and medium-sized businesses.
Product diversification fuels expansion and competitiveness in the neuroendovascular coil market. As the need for minimally invasive treatments for brain aneurysms and other neurovascular diseases increases, manufacturers diversify their product lines to provide more effective, advanced, and personalized solutions for different clinical cases. Product line extension includes the creation of second-generation coil technologies, i.e., hydrogel-coated coils, bioactive coils, and intricately shaped 3D-shaped coils that enable improved aneurysm filling, healing, and recurrence reduction. Firms are also developing coil delivery systems with innovation, enhancing precision, control, and flexibility for neurointerventional work in fragile cerebral vessels.
Regional growth is one of the primary strategies for expansion in the neuroendovascular coil market, as players attempt to penetrate emerging markets and consolidate their position in mature geographies. With increasing global prevalence of neurological conditions, most notably brain aneurysms and strokes, growth into new geographies allows players to gain access to greater patient bases, spread revenue streams, and minimize reliance on saturated geographies.
Report Coverage & Deliverables
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Type Insights
Platinum coils bare stand atop the market because of their well-established clinical effectiveness and extensive usage. They are the first generation of neuroendovascular coils that enjoy a proven history of use in treating cerebral aneurysms and other neurovascular pathologies. Bare platinum coils perform excellently for small aneurysms with uncomplicated geometries, with a guaranteed occlusion and rupture prevention. The bare platinum coils are also economical in nature and thus are available in developed and resource-constrained environments where affordability is important. Their compatibility with generic neurointerventional devices, like catheters and microcatheters, makes them widely available in all the hospitals, surgery centers, and clinics. Additionally, bare platinum coils have garnered widespread regulatory clearances from the FDA and CE and are globally well-accepted by clinicians. Their long-term clinical evidence of safety and efficacy also cements their status as the first choice for most neurointerventional procedures, especially in treating uncomplicated aneurysms and repeat treatments.
The hydrogel-coated coils market is anticipated to have the highest CAGR in the market because of their innovative nature and the substantial clinical benefits over basic bare platinum coils. Hydrogel-coated coils are supplemented with a hydrophilic coating that expands their volume and stability after deployment within an aneurysm, resulting in improved occlusion and minimizing recanalization risk. Their capacity to form a stronger and more resilient thrombus and better volumetrically fill aneurysms fuels increasing use, especially in the parts of the world where advanced neuro interventions are gaining popularity. Further, these coils are configured to minimize procedural complications, like coil migration or coil compaction, resulting in better patient outcomes and shorter recovery times, making them more attractive to patients and healthcare providers.
Application Insights
The cerebral aneurysm application segment holds the largest market share because of the high worldwide prevalence of aneurysms and the proven clinical effectiveness of coiling as a first-line treatment, especially in the case of unruptured and ruptured aneurysms. A cerebral aneurysm refers to a focal balloon outpouching of a cerebral artery wall that can rupture and lead to subarachnoid hemorrhage, a potentially life-threatening type of stroke. Neuroendovascular coiling is now the standard of care for most of these aneurysms due to the fact that it is a minimally invasive technique, has a lower risk of procedure compared to surgery with clipping, and carries shorter recovery times and better outcomes in terms of neurology. Additionally, cerebral aneurysms have the highest incidence of procedures involving neuroendovascular coils and as a result have the highest volume and revenue-dominant application. Growing populations, primarily in more developed areas, also play an important role in this trend, as incidence of aneurysm rises with age. Furthermore, growing awareness, screening of patients, and public health programs for the prevention of stroke will be expected to support increasing rates of procedure.
The cerebral infarction segment is anticipated to register a high CAGR in the market, mainly influenced by an increase in the worldwide burden of ischemic strokes, improvements in interventional devices technology, and changing treatment patterns that broaden coiling and adjunctive neurovascular therapies applications. Cerebral infarction, or better known as ischemic stroke, results when an artery supplying blood to the brain is blocked by a clot. Although mechanical thrombectomy with stent retrievers and aspiration catheters is still the mainstay for large vessel occlusions, techniques of coiling and embolization are being utilized for complications related to stroke like pseudoaneurysms, arteriovenous fistulae, or hemorrhagic transformation due to infarction.
End Use Insights
The hospital segment leads the market because of its sophisticated infrastructure, expert medical staff, and wide-ranging emergency care facilities. Hospitals are the central facilities with sophisticated instruments for neurointerventional suites, biplane imaging equipment, and intensive care units needed for advanced procedures like intracranial aneurysm coiling, embolization of arteriovenous malformation, and acute ischemic stroke treatment. Such facilities facilitate 24/7 emergency interventions essential for hemorrhagic stroke care and receive referrals from smaller clinics and local centers. Having trained interventional neuroradiologists, neurosurgeons, and neurologists allows hospitals to manage a more diverse range of cases, including ruptured or complex aneurysms that need multidisciplinary care.
The ambulatory surgery centers (ASCs) market is anticipated to expand with the highest CAGR due to healthcare system movement toward cost-effectiveness, patient convenience, and technology miniaturization. ASCs provide a streamlined and outpatient-centric care model that supports quicker turnaround times, lower costs of hospitalization, and fewer infection chances compared with conventional hospitals. With the evolution of minimally invasive neurointerventional procedures and the availability of softer, more deliverable coils, most less complicated cerebral aneurysms can now be treated safely in ASC facilities. Furthermore, the implementation of portable imaging technology and miniaturized catheterization labs has increased the ability of ASCs to perform neurovascular procedures previously limited to tertiary centers.
Regional Insights
North America neuroendovascular coil market led the overall market with a revenue share of 36.71% in 2024, owing to its developed healthcare infrastructure, high level of disease awareness, strong base of global leading medical device companies, and strong regulatory systems. The dominance of the region is supported by a number of critical factors behind it being at the forefront of innovation and implementation of neurointerventional devices. North America is served by a wide network of stroke centers, specialized neurovascular units, and hospitals that possess state-of-the-art diagnostic and interventional facilities. All of these centers can carry out advanced, complex procedures like coil embolization, usually with the advantage of the newest generation devices.
U.S. Neuroendovascular Coil Market Trends
The United States contributed the highest proportion in North America neuroendovascular coil market in 2024. One of the main drivers of the neuroendovascular coil market in the United States is the rising prevalence of cerebral aneurysms and strokes. This shift generates an expanding clinical demand for effective, minimally invasive procedures, which directly influences coil embolization treatments demand. As per the National Institutes of Health, in the United States, cerebrovascular conditions, which encompass stroke and other conditions, impact approximately 800,000 individuals every year, rendering stroke the fifth most common cause of mortality.
Clinical trials seriously propel the neuroendovascular coil market by producing robust clinical data that supports the safety, efficacy, and long-term results of coil systems utilized to treat cerebral aneurysms and other neurovascular diseases. Further, clinical trials are necessary to gain regulatory approvals from the FDA, furnish the data to support product clearance or approval, and present manufacturers with the opportunity to feature innovative characteristics, including bioactive, hydrogel-coated, or stretch-resistant coils, that enhance clinical performance and patient outcomes. By making products stand out in a competitive marketplace, trials drive brand-specific demand. Moreover, clinical trial information is important in informing reimbursement decisions by showing cost-effectiveness and enhanced healthcare outcomes, prompting insurance companies to provide coverage for such procedures. Consequently, clinical trials confirm established technologies, drive the uptake of newer coil systems, increase treatment indications, and eventually drive market growth.
Europe Neuroendovascular Coil Market Trends
Europe neuroendovascular coil market shared a significant market share in 2024. Europe has a severe burden of cerebrovascular diseases like intracranial aneurysms, subarachnoid hemorrhage, and ischemic stroke. Stroke accounts for the second most common cause of mortality in Europe, with more than 1 million deaths each year, as per the European Stroke Organisation (ESO). Cases of unruptured intracranial aneurysms detected during imaging for other reasons are also on the increase. With the population still aging and risk factors such as hypertension, obesity, and smoking still common, the clinical need for neuroendovascular interventions, such as coiling, has increased dramatically.
The Stroke Action Plan for Europe (SAP-E) in 2018 is a joint action coordinated by the ESO and Stroke Alliance for Europe (SAFE). It delivers a solid blueprint for the enhancement of stroke care in Europe by the year 2030. Prevention, treatment, rehabilitation, and long-term care are all tackled within the plan, with a specific emphasis on minimizing the burden of stroke and maximizing the quality of life for stroke survivors. It informs future healthcare investments, neurointerventional services, and market opportunities, including for neuroendovascular devices like coils.
"Stroke can be prevented and treated because of the major advances during recent decades. Nevertheless, a considerable gap remains between knowledge and provision of stroke services even with the high cost-effectiveness of stroke treatment. All European stroke patients should be given access to the optimal best evidence-based treatment to provide the optimal quality of life after stroke. Execution of the Stroke Action Plan for Europe will assist us in this regard."- Professor of Neurology and Chair of the Stroke Action Plan for Europe
The UK neuroendovascular coil market is anticipated to rise extensively during the forecast period. The UK is experiencing the rising numbers of patients with intracranial aneurysms and ischemic strokes, mainly elderly patients. The Stroke Association UK stated that more than 100,000 strokes happen every year and around 1.3 million individuals live with the stroke effect. Since aneurysms are diagnosed by imaging, increasing numbers of patients are being presented for preventative coiling, driving demand. According to the NHS, approximately 1 in 15,000 individuals have a ruptured brain aneurysm annually in England. The UK National Health Service has committed significantly to establishing a national network of stroke care, including specialized stroke units, hyperacute stroke centers, and mechanical thrombectomy. Most of these centers can carry out neuroendovascular procedures, such as coil embolization for aneurysms. The Long-Term Plan of NHS England involves increasing access to neurointerventional and thrombectomy, favoring market expansion.
The Germany neuroendovascular coil market is expanding. Germany harbors a high incidence of neurovascular diseases, especially in the elderly population. The NIH reports that stroke continues to be a major cause of disability and mortality in Germany. The percentage of people older than 65 years is gradually on the rise. This group of people is more prone to aneurysms and stroke, which increases demand for neuroendovascular treatments such as coiling. German hospitals like the Center for Neurovascular Diseases Tübingen and the Germans Trias i Pujol Research Institute (IGTP) are aggressively involved in neurovascular studies and multi-center trials, creating a fast pace for the adoption and introduction of new neuroendovascular devices. The nation has a robust pool of neurosurgeons and interventional neuroradiologists who are well-trained in handling neuroendovascular coils, favoring the growth of the market. The percentage of the population aged 65 and over is on the rise. This age group is more vulnerable to aneurysm and stroke, directly increasing the need for neuroendovascular treatments such as coiling. Based on EUROSTAT, the percentage of the population 65 years and older was 22.40% in December 2024.
Asia Pacific Neuroendovascular Coil Market Trends
The Asia-Pacific neuroendovascular coil market is witnessing the fastest growth globally due to demographic, epidemiological, technological, and healthcare infrastructure developments. A rapidly aging population across countries such as Japan, China, and South Korea has led to a higher incidence of neurovascular disorders such as cerebral aneurysms and strokes, which are key indications for endovascular coiling. Additionally, the increasing prevalence of risk factors such as hypertension, diabetes, and sedentary lifestyles has contributed to a surge in demand for neurointerventional procedures. Improved access to advanced diagnostic tools like MRI, CT, and digital subtraction angiography (DSA) has enabled earlier detection of aneurysms and arteriovenous malformations, leading to preventive coiling interventions. According to the Journal of Asian Pacific Society of Cardiology. The overall prevalence of hypertension in the Asia-Pacific region ranged between 10.6% and 48.3%. Furthermore, investments in healthcare infrastructure, particularly in emerging economies such as India and China, have expanded the availability of specialized neurosurgical and endovascular services. The region also benefits from rising awareness among patients and healthcare professionals regarding the advantages of minimally invasive neurointerventional techniques, which offer quicker recovery and reduced post-operative complications compared to traditional surgery.
The neuroendovascular coil market in India is anticipated to witness the significant growth in the Asia Pacific market over the forecast periodIndia's growing burden of cerebrovascular diseases is one of the most significant factors driving demand for neuroendovascular coils. Stroke is the second leading cause of death and a significant cause of long-term disability in India, with ischemic and hemorrhagic strokes becoming common. In India, the burden of stroke is substantial and growing, with profound implications for the healthcare system and public health. Stroke ranks as the fourth leading cause of death and the fifth leading cause of disability in the country. The incidence of stroke in India ranges from 119 to 145 per 100,000 population annually, with a higher prevalence observed in urban areas compared to rural regions. The rising prevalence of risk factors such as hypertension, diabetes, obesity, smoking, and sedentary lifestyles, particularly among younger populations, is accelerating the incidence of brain aneurysms and other neurovascular conditions. This epidemiological trend is creating an urgent need for minimally invasive, effective treatment options like coil embolization. According to government of India, as of March 2025, a total of 42.01 million individuals have received treatment for hypertension, while 25.27 million have been treated for diabetes.
China neuroendovascular coil market is growing. Driven by the rising incidence of neurovascular diseases, mainly due to the country’s aging population and increasing prevalence of risk factors such as hypertension, diabetes, and smoking. China faces one of the highest stroke burdens globally, with millions of new cases annually, fueling demand for effective neurointerventional treatments such as coil embolization. Furthermore, advancements in coil technology, such as developing hydrogel-coated and bioactive coils, are improving treatment efficacy and expanding the scope of conditions that can be managed endovascularly. These innovations are complemented by improved procedural tools, such as adjunctive stents and microcatheters, which enhance precision and outcomes. The expansion of neurointerventional capabilities across China has also played a key role. Tertiary hospitals are being upgraded, and specialized stroke centers are proliferating, allowing for more widespread access to complex procedures. Additionally, government-supported training programs have significantly increased the number of skilled neuro interventionists. The Chinese government’s ongoing healthcare reforms, under initiatives like “Healthy China 2030,” are further supporting the adoption of advanced medical technologies.
Middle East and Africa Neuroendovascular Coil Market Trends
The Middle East and Africa (MEA) neuroendovascular coil market is experiencing significant growth, due to increase in the prevalence of stroke, brain aneurysms, and arteriovenous malformations, fueled by aging populations, urbanization, and lifestyle-related risk factors such as hypertension, smoking, obesity, and diabetes. These trends create a growing demand for advanced neurointerventional procedures, including the use of neuroendovascular coils for aneurysm embolization. Governments in the Gulf Cooperation Council (GCC) countries, such as Saudi Arabia, the UAE, and Qatar, are making significant investments in healthcare modernization. New hospitals and specialized centers are being established, with enhanced access to neurosurgery and interventional neuroradiology services. These developments support the adoption of advanced devices such as neuroendovascular coils.
Key Neuroendovascular Coil Company Insights
Some key companies operating in the market includeStryker, Balt, Johnson & Johnson, Boston Scientific Corporation, Medtronic, and TERUMO CORPORATION. Strategic initiatives involve mergers, acquisitions, and collaborations to broaden product offerings and market presence, alongside focused research and development to improve product efficacy and utilize innovative technologies.
Key Neuroendovascular Coil Companies
The following are the leading companies in the neuroendovascular coil market. These companies collectively hold the largest market share and dictate industry trends.
- Penumbra, Inc
- Kaneka Medical Europe N.V.
- Stryker
- Lepu Medical Technology (Beijing) Co.,Ltd
- Balt
- NeuroSafe Medical Co., Ltd.
- Johnson & Johnson
- Boston Scientific Corporation
- Medtronic
- Terumo Corporation
Recent Developments
-
In January 2025, Kaneka Corporation, a Tokyo-based healthcare company, announced the acquisition of a 96.8% stake in EndoStream Medical Ltd., an Israeli medical device startup headquartered in Or Akiva. Kaneka's broader strategy is to expand its healthcare business and strengthen its position in the neurovascular treatment market.
-
In May 2023,CERENOVUS, Inc., a part of Johnson & Johnson MedTech, has announced the U.S. commercial launch of its latest neurovascular innovation, the CEREPAK Detachable Coils, and confirmed that the first patient cases have been successfully performed.
-
In December 2022, Stryker has received FDA 510(k) clearance for its Target Tetra Detachable Coil — a next-generation neuroendovascular coil designed to treat small cerebral aneurysms.
Neuroendovascular Coil Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 1.11 billion |
|
Revenue forecast in 2030 |
USD 1.52 billion |
|
Growth rate |
CAGR of 6.5% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018 - 2023 |
|
Forecast period |
2025 - 2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
|
Segments covered |
Type, application, end use, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Penumbra; Inc; Kaneka Medical Europe N.V.; Stryker; Lepu Medical Technology (Beijing) Co. Ltd; Balt; NeuroSafe Medical Co., Ltd.; Johnson & Johnson; Boston Scientific Corporation; Medtronic; Terumo Corporation |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Global Neuroendovascular Coil Market Report Segmentation
-
Type Outlook (Revenue, USD Million, 2018 - 2030)
-
Bare Platinum Coils
-
Hydrogel-Coated Coils
-
-
Application Outlook (Revenue, USD Million, 2018 - 2030)
-
Cerebral Infarction
-
Cerebral Aneurysm
-
Arteriovenous Malformation (AVM)
-
Others
-
-
End Use Outlook (Revenue, USD Million, 2018 - 2030)
-
Hospitals
-
Ambulatory Surgery Centers
-
Specialty Clinics
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy